IMPAIRED CELL-MEDIATED-IMMUNITY IN EXPERIMENTAL ABDOMINAL SEPSIS AND THE EFFECT OF INTERLEUKIN-2

被引:0
|
作者
GOUGH, DB [1 ]
JORDAN, A [1 ]
MANNICK, JA [1 ]
RODRICK, ML [1 ]
机构
[1] HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG, 75 FRANCIS ST, BOSTON, MA 02115 USA
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
A murine model of experimental sepsis, ie, cecal ligation and puncture, was used to determine the potential effects of infection on in vitro cell-mediated immunity. Following cecal ligation and puncture, in vitro responses of mouse splenocytes to mitogens (phytohemagglutinin and concanavalin A), the effects of in vitro interleukin 2 on these responses, and the impact of in vivo interleukin 2 on survival were studied. Compared with controls (sham cecal ligation and puncture), phytohemagglutinin responses 1 day after cecal ligation and puncture were enhanced (43%+/-17%, n = 9), phytohemagglutinin and concanavalin A responses at day 4 were suppressed (45.5%+/-4.4% and 57.5%+/-5.6%), and, by day 7, phytohemagglutinin and concanavalin A responses were approaching values in mice treated by sham cecal ligation and puncture. Suppressed phytohemagglutinin responses at day 4 after cecal ligation and puncture were restored to normal with in vitro interleukin 2 (61 052+/-3407 cpm for cecal ligation and puncture and 64 643+/-4727 cpm for sham cecal ligation and puncture). Mortalities following cecal ligation and puncture were identical at day 1 after cecal ligation and puncture (6/20) for both interleukin 2- and vehicle-treated groups; thereafter, interleukin 2-treated groups fared better. At day 1 after cecal ligation and puncture, the mean spleen cell phytohemagglutinin response was enhanced (43.8%+/-17%, n = 9) compared with sham cecal ligation and puncture (= 10). By day 4, the responses to both concanavalin A and phytohemagglutinin were suppressed (45.5%+/-4.4% and 57.5%+/-5.6%, respectively). Responses at day 7 approached those of controls given sham cecal ligation and puncture. Sepsis causing a temporary impairment of cell-mediated immunity may be a factor in the frequent coexistence of altered cell-mediated immunity and sepsis, and interleukin 2 may have a role in limiting the adverse effects of sepsis.
引用
收藏
页码:859 / 863
页数:5
相关论文
共 50 条
  • [21] IMPAIRED CELL-MEDIATED-IMMUNITY (CMI) AFTER TRAUMA IN CHILDHOOD
    STEIN, MD
    LOBE, TE
    CIRCULATORY SHOCK, 1986, 18 (04) : 362 - 363
  • [22] CELL-MEDIATED-IMMUNITY
    DEEPE, GS
    CURRENT OPINION IN INFECTIOUS DISEASES, 1990, 3 (03) : 356 - 360
  • [23] CELL-MEDIATED-IMMUNITY
    不详
    ALLERGOLOGIE, 1995, 18 (10) : 477 - 480
  • [24] CELL-MEDIATED-IMMUNITY IN SARCOIDOSIS - EFFECT OF CORTICOSTEROIDS
    GROSS, NJ
    LENNOXHOLT, PJ
    BRITISH JOURNAL OF DISEASES OF THE CHEST, 1977, 71 (01): : 25 - 34
  • [25] THE EFFECT OF OPERATIVE STRESS ON CELL-MEDIATED-IMMUNITY
    ZIMIN, YI
    SUKHIKH, GT
    NALIVAIKO, ES
    VANKO, LV
    MEERSON, FZ
    VESTNIK AKADEMII MEDITSINSKIKH NAUK SSSR, 1985, (08): : 30 - 34
  • [26] STIMULATING EFFECT OF TRIIODOTHYRONINE ON CELL-MEDIATED-IMMUNITY
    BALAZS, C
    LEOVEY, A
    SZABO, M
    BAKO, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (01) : 19 - 23
  • [27] EFFECT OF MURINE CYTOMEGALOVIRUS ON CELL-MEDIATED-IMMUNITY
    HOWARD, RJ
    BALFOUR, HH
    SEIDEL, MV
    SIMMONS, RL
    NAJARIAN, JS
    TRANSPLANTATION PROCEEDINGS, 1977, 9 (01) : 355 - 358
  • [28] CELL-MEDIATED-IMMUNITY IN CHRONIC-RENAL-FAILURE - INHIBITION OF BLASTOGENESIS AND INTERLEUKIN-2 (IL-2) OF PRODUCTION BY UREMIC SERUM
    CHOI, KH
    KIM, YK
    HA, SK
    LEE, HY
    HAN, DS
    LEE, BK
    KIM, JD
    KIDNEY INTERNATIONAL, 1991, 39 (05) : 1064 - 1064
  • [29] IMPAIRED CELL-MEDIATED-IMMUNITY IN IDIOPATHIC MEMBRANOUS NEPHROPATHY MEDIATED BY SUPPRESSOR CELLS
    MATSUMOTO, K
    OSAKABE, K
    HATANO, M
    CLINICAL NEPHROLOGY, 1983, 19 (04) : 213 - 214
  • [30] EFFECT OF UREMIA AND DIALYSIS ON CELL-MEDIATED-IMMUNITY
    WOJTULEWICZKURKUS, J
    KLEPACKA, J
    SKOPINSKA, E
    GORSKI, A
    NOWACZYK, M
    ORLOWSKI, T
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 1978, 26 (1-6) : 997 - 1000